HeartSciences Inc. (HSCS)
NASDAQ: HSCS · Real-Time Price · USD
2.390
-0.050 (-2.05%)
At close: Jul 24, 2026, 4:00 PM EDT
2.351
-0.039 (-1.65%)
After-hours: Jul 24, 2026, 7:54 PM EDT
HeartSciences Revenue
In the fiscal year ending April 30, 2026, HeartSciences had annual revenue of $4.32K, down -0.71%.
Revenue (ttm)
$4.32K
Revenue Growth
-0.71%
P/S Ratio
1,763.09
Revenue / Employee
$288
Employees
15
Market Cap
7.61M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2026 | 4.32K | -31.00 | -0.71% |
| Apr 30, 2025 | 4.35K | -14.25K | -76.61% |
| Apr 30, 2024 | 18.60K | 13.45K | 261.17% |
| Apr 30, 2023 | 5.15K | -9.22K | -64.17% |
| Apr 30, 2022 | 14.37K | -11.23K | -43.86% |
| Apr 30, 2021 | 25.60K | -38.58K | -60.11% |
| Apr 30, 2020 | 64.18K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Trinity Biotech | 43.79M |
| Vivos Therapeutics | 19.57M |
| Picard Medical | 5.47M |
| IceCure Medical | 3.57M |
| VolitionRx | 2.47M |
| Sintx Technologies | 1.03M |
| Co-Diagnostics | 718.17K |
| Nexalin Technology | 275.58K |
HSCS News
- 1 day ago - HeartSciences Files Its Fiscal 2026 Annual Report on Form 10-K - GlobeNewsWire
- 1 day ago - HeartSciences Proxy statement: Proxy filing - Filings
- 1 day ago - HeartSciences Annual report: Q4 2026 - Filings
- 2 days ago - HeartSciences Proxy statement: Proxy filing - Filings
- 14 days ago - HeartSciences Proxy statement: Proxy filing - Filings
- 4 weeks ago - HeartSciences Proxy statement: Proxy filing - Filings
- 4 weeks ago - HeartSciences Proxy statement: Proxy filing - Filings
- 4 weeks ago - HeartSciences Proxy statement: Proxy filing - Filings